Indications
Therapeutic Asset Ratings
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Epirubicin
Progesterone-Receptor Negative Breast Cancer
Massachusetts General Hospital
P2
BB
(66)
Fludarabine
B-Cell Non-Hodgkin Lymphoma
Swiss Cancer Institute
P2
BB
(66)
Fludarabine
Congenital Amegakaryocytic Thrombocytopenia
Fred Hutchinson Cancer Center
P2
BB
(66)
Fludarabine
Hematopoietic And Lymphoid System Neoplasm
National Cancer Institute (NCI)
P2
BB
(66)
Fluorouracilum
Cancer Of Unknown Primary Site
Alliance for Clinical Trials in Oncology
P2
BB
(66)
Imatinib
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
The University of Hong Kong
P2
BB
(66)
Irinotecan
Pancreatic Acinar Cell Carcinoma
Artios Pharma Ltd
P2
BB
(66)
Lenalidomide
MALT Lymphoma
Yazeed Sawalha
P2
BB
(66)
Lenalidomide
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
P2
BB
(66)
Melphalan
Graft Versus Host Disease
City of Hope Medical Center
P2
BB
(66)
Melphalan
Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome
City of Hope Medical Center
P2
BB
(66)
Methotrexate
Leukemia, Myeloid, Accelerated-Phase
University of Michigan Rogel Cancer Center
P2
BB
(66)
Methotrexate
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
University of Michigan Rogel Cancer Center
P2
BB
(66)
Mitoxantrone
Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome
Institut de Recherches Internationales Servier
P2
BB
(66)
Mogamulizumab
Adult T-Cell Leukemia/Lymphoma
Memorial Sloan Kettering Cancer Center
P2
BB
(66)
Nivestim
Acute Biphenotypic Leukemia
Ossium Health, Inc.
P2
BB
(66)
Nivestim
Mantle Cell Lymphoma
Fred Hutchinson Cancer Center
P2
BB
(66)
Nivestim
Neoplasm
Ankara Etlik City Hospital
P2
BB
(66)
Obinutuzumab
B-Cell Non-Hodgkin Lymphoma
Brown University
P2
BB
(66)
Obinutuzumab
Richter Transformation
Christine Ryan
P2
BB
(66)
Olaparib
Malignant Pancreatic Neoplasm
MOMA Therapeutics
P2
BB
(66)
Pembrolizumab
Estrogen-Receptor Negative Breast Cancer
Massachusetts General Hospital
P2
BB
(66)
Pembrolizumab
Primary Mediastinal Large B-Cell Lymphoma
Seda S. Tolu
P2
BB
(66)
Pembrolizumab
Progesterone-Receptor Negative Breast Cancer
Massachusetts General Hospital
P2
BB
(66)
Pembrolizumab
Fallopian Tube Carcinoma
Roswell Park Cancer Institute
P2
BB
(66)
Showing 2401 to 2425 of 42,301 assets
Previous
Page 97 of 1693
Next